Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBK2-ICG for Fluorescence-Guided Imaging of Brain Tumors
NCT07438860Phase 1Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SBK2-ICG in brain tumor and glioma. Primary endpoint: Adverse Events at 14 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SBK2-ICG
03
Conditions
brain tumorglioma
Beyond the preview
Go deeper on NCT07438860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438860.